Instrument Inactif

Communiqués Forest Laboratories, Inc.

Actions

US3458381064

Produits pharmaceutiques

Cours en clôture NYSE Autres places de cotation
- ^USD	-

28/04/14	Bank of America : Wall Street ouvre en hausse, les pharmaceutiques en vue	RE
28/04/14	Wall Street ouvre en hausse, les pharmaceutiques en vue	RE

Communiqués

30/06/14	Forest Laboratories : Actavis and Forest Receive U.S. FTC Clearance for Actavis’ Proposed Acquisition of Forest	BU
30/06/14	Forest Laboratories : Actavis and Forest Announce Preliminary Stockholder Merger Consideration Election Results	BU
23/06/14	Forest Laboratories : Announces Positive Topline Results from Three Phase III Trials for Vilazodone in the Treatment of Generalized Anxiety Disorder (GAD)	BU
23/06/14	Forest Laboratories : Actavis and Forest Laboratories Announce Appointment of C. David Nicholson, PhD to lead Actavis Global Brands Research and Development	BU
20/06/14	Forest Laboratories : to Present Cariprazine Data at the International College of Neuropsychopharmacology World Congress	BU
18/06/14	Forest Laboratories : Obtains Six Months U.S. Pediatric Exclusivity for NAMENDA® and NAMENDA XR®	BU
17/06/14	Forest Laboratories : COPD Foundation Releases Groundbreaking COPE Survey Results: Low Patient Awareness About COPD Exacerbations Poses Barrier to Effective Management	BU
12/06/14	Forest Laboratories : Announces Receipt of Requisite Consents and Expiration of Consent Solicitations for Certain of its Senior Notes	BU
10/06/14	Forest Laboratories : Announces Intention to Continue Marketing Both NAMENDA® TABLETS and Once-Daily NAMENDA XR® Into the Fall of 2014	BU
09/06/14	Forest Laboratories : Extends Expiration Time of Consent Solicitations to Eliminate Existing Registration Rights Obligations on Certain of its Senior Notes	BU
30/05/14	Forest Laboratories : Announces Publication in The Lancet of Pivotal Phase III Hypertension Trial of the Fixed-Dose Combination of Nebivolol/Valsartan	BU
22/05/14	Forest Laboratories : Commences Consent Solicitations to Eliminate Existing Registration Rights Obligations on Certain of its Senior Notes	BU
16/05/14	Forest Laboratories : to Present Data about Aclidinium, Aclidinium/Formoterol Combination, and Roflumilast at the American Thoracic Society International Conference	BU
16/05/14	Forest Laboratories : to Present Nebivolol/Valsartan Fixed-Dose Combination Data at the American Society of Hypertension Annual Scientific Meeting	BU
13/05/14	Forest Laboratories : Prestigious Recognitions, Financial Results, Presentations, Study Analysis, and SEC Filings - Analyst Notes on WellPoint, NPS Pharma, Novartis, Cigna and Forest	PR
02/05/14	Forest Laboratories : to Present Data about Levomilnacipran and Vilazodone at the American Psychiatric Association 167th Annual Meeting	BU
01/05/14	Forest Laboratories : Ironwood and Forest to Present Linaclotide Data at Digestive Disease Week® 2014	BU
29/04/14	Forest Laboratories : Reports Fiscal Year Fourth Quarter 2014	BU
29/04/14	Forest Laboratories : Acquisition of Furiex Pharmaceuticals, Inc. by Forest Laboratories, Inc. May Not Be in Shareholders' Best Interests	PR
28/04/14	Forest Laboratories : FURIEX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Furiex Pharmaceuticals	PR
28/04/14	Forest Laboratories : Joins ConvergeHEALTH by Deloitte's Rapid Learning Network in Collaboration with Intermountain Healthcare to Support Insights into Optimal Patient Care	PR
28/04/14	Forest Laboratories : Furiex Pharmaceuticals (FURX) Shareholder Alert - Andrews & Springer LLC Is Seeking More Cash for Shareholders of Furiex Pharmaceuticals, Inc.	PR
28/04/14	Forest Laboratories : Dates for Upcoming Earnings Releases -- Research on Eaton, Cameco, Huntsman, and Forest Laboratories	PR
28/04/14	Forest Laboratories : Investor Conference Call Regarding Acquisition of Furiex Pharmaceuticals To Take Place at 9:30 AM EST	BU
28/04/14	Forest Laboratories : Furiex - Investor Alert - Tripp Levy Pllc Seeks Higher Price For Shareholders	PR